{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T15:58:59Z","timestamp":1778860739405,"version":"3.51.4"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T00:00:00Z","timestamp":1770595200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T00:00:00Z","timestamp":1773273600000},"content-version":"vor","delay-in-days":31,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med"],"DOI":"10.1186\/s12916-026-04693-3","type":"journal-article","created":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T09:48:25Z","timestamp":1770630505000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Optimizing drug-resistant tuberculosis diagnosis: cost-effectiveness of rapid molecular and phenotypic assays in South Africa"],"prefix":"10.1186","volume":"24","author":[{"given":"Ginenus","family":"Fekadu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tadesse","family":"Tolossa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lan","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Habteyes Hailu","family":"Tola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tesfaye Regassa","family":"Feyissa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lianping","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shanquan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathorn","family":"Chaiyakunapruk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elias","family":"Asfaw","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Siegel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wai Kit","family":"Ming","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,9]]},"reference":[{"key":"4693_CR1","volume-title":"Global Tuberculosis Report 2024","author":"World Health Organization","year":"2024","unstructured":"World Health Organization. Global Tuberculosis Report 2024. Geneva: World Health Organization; 2024."},{"key":"4693_CR2","volume-title":"WHO consolidated guidelines on tuberculosis. Module 4: treatment - drug-resistant tuberculosis treatment, 2022 update","author":"World Health Organization","year":"2022","unstructured":"World Health Organization. WHO consolidated guidelines on tuberculosis. Module 4: treatment - drug-resistant tuberculosis treatment, 2022 update. WHO; 2022."},{"key":"4693_CR3","volume-title":"WHO consolidated guidelines on tuberculosis: module 3: Diagnosis: Rapid diagnostics for tuberculosis detection","author":"World Health Organization","year":"2024","unstructured":"World Health Organization. WHO consolidated guidelines on tuberculosis: module 3: Diagnosis: Rapid diagnostics for tuberculosis detection. Geneva: WHO; 2024."},{"key":"4693_CR4","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.870768","volume":"13","author":"KA Yusoof","year":"2022","unstructured":"Yusoof KA, Garc\u00eda JI, Schami A, Garcia-Vilanova A, Kelley HV, Wang S-H, et al. Tuberculosis phenotypic and genotypic drug susceptibility testing and immunodiagnostics: a review. Front Immunol. 2022;13:870768.","journal-title":"Front Immunol"},{"key":"4693_CR5","unstructured":"Zweynert A. Drug-resistant TB threatens to kill 75 million people by 2050, Cost $16.7 Trillion. London: Reuters; 2022. https:\/\/www.reuters.com\/article\/business\/healthcare-pharmaceuticals\/drug-resistant-tb-threatens-to-kill-75-million-people-by-2050-cost-167-trilli-idUSKBN0MK004\/."},{"issue":"1","key":"4693_CR6","doi-asserted-by":"publisher","DOI":"10.3390\/pathogens13010027","volume":"13","author":"K Naidoo","year":"2023","unstructured":"Naidoo K, Perumal R, Ngema SL, Shunmugam L, Somboro AM. Rapid diagnosis of drug-resistant tuberculosis\u2013opportunities and challenges. Pathogens. 2023;13(1):27.","journal-title":"Pathogens"},{"key":"4693_CR7","volume-title":"WHO standard: universal access to rapid tuberculosis diagnostics","author":"World Health Organization","year":"2023","unstructured":"World Health Organization. WHO standard: universal access to rapid tuberculosis diagnostics. WHO; 2023."},{"issue":"11","key":"4693_CR8","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1056\/NEJMoa1614915","volume":"377","author":"YL Xie","year":"2017","unstructured":"Xie YL, Chakravorty S, Armstrong DT, Hall SL, Via LE, Song T, et al. Evaluation of a rapid molecular drug-susceptibility test for tuberculosis. N Engl J Med. 2017;377(11):1043\u201354.","journal-title":"N Engl J Med"},{"key":"4693_CR9","doi-asserted-by":"publisher","DOI":"10.2147\/idr.s381643","author":"L Nandlal","year":"2022","unstructured":"Nandlal L, Perumal R, Naidoo K. Rapid molecular assays for the diagnosis of drug-resistant tuberculosis. Infect Drug Resist. 2022. https:\/\/doi.org\/10.2147\/idr.s381643.","journal-title":"Infect Drug Resist"},{"key":"4693_CR10","doi-asserted-by":"crossref","unstructured":"Pillay S, Steingart KR, Davies GR, Chaplin M, De Vos M, Schumacher SG, et al. Xpert MTB\/XDR for detection of pulmonary tuberculosis and resistance to isoniazid, fluoroquinolones, ethionamide, and amikacin. Cochrane Database Syst Rev. 2022;5(5):Cd014841.","DOI":"10.1002\/14651858.CD014841.pub2"},{"key":"4693_CR11","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.cca.2022.06.020","volume":"533","author":"M Lin","year":"2022","unstructured":"Lin M, Chen YW, Li YR, Long LJ, Qi LY, Cui TT, et al. Systematic evaluation of line probe assays for the diagnosis of tuberculosis and drug-resistant tuberculosis. Clin Chim Acta. 2022;533:183\u2013218.","journal-title":"Clin Chim Acta"},{"issue":"1","key":"4693_CR12","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01075-2016","volume":"49","author":"RR Nathavitharana","year":"2017","unstructured":"Nathavitharana RR, Cudahy PG, Schumacher SG, Steingart KR, Pai M, Denkinger CM. Accuracy of line probe assays for the diagnosis of pulmonary and multidrug-resistant tuberculosis: a systematic review and meta-analysis. Eur Respir J. 2017;49(1):1601075.","journal-title":"Eur Respir J"},{"key":"4693_CR13","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2024.1349715","volume":"15","author":"A Liu","year":"2024","unstructured":"Liu A, Liu S, Lv K, Zhu Q, Wen J, Li J, et al. Rapid detection of multidrug resistance in tuberculosis using nanopore-based targeted next-generation sequencing: a multicenter, double-blind study. Front Microbiol. 2024;15:1349715.","journal-title":"Front Microbiol"},{"key":"4693_CR14","doi-asserted-by":"crossref","unstructured":"Husereau D, Drummond M, Augustovski F, de Bekker-Grob E, Briggs A, Carswell C, et al. CHEERS 2022 ISPOR Good Research Practices Task Force. Consolidated health economic evaluation reporting standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. Value Health. 2022;25(1):3\u20139.","DOI":"10.1016\/j.jval.2021.11.1351"},{"key":"4693_CR15","unstructured":"Department of Health - South Africa. Clinical management of rifampicin-resistant tuberculosis: updated clinical reference guide 2023. https:\/\/www.health.gov.za\/wp-content\/uploads\/2023\/10\/Updated-RR-TB-Clinical-Guidelines-September-2023.pdf."},{"key":"4693_CR16","volume-title":"WHO consolidated guidelines on tuberculosis: module 4: treatment: drug-susceptible tuberculosis treatment","author":"World Health Organization","year":"2022","unstructured":"World Health Organization. WHO consolidated guidelines on tuberculosis: module 4: treatment: drug-susceptible tuberculosis treatment. Geneva: WHO; 2022."},{"key":"4693_CR17","unstructured":"Department of Health-South Africa. South African National TB Guidelines - Adults: National Department of Health; 2017. https:\/\/www.knowledgehub.org.za\/system\/files\/elibdownloads\/2022-09\/TB%20Adult_2017.pdf."},{"issue":"11","key":"4693_CR18","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2019-031663","volume":"9","author":"NR Mvelase","year":"2019","unstructured":"Mvelase NR, Balakrishna Y, Lutchminarain K, Mlisana K. Evolving rifampicin and isoniazid mono-resistance in a high multidrug-resistant and extensively drug-resistant tuberculosis region: a retrospective data analysis. BMJ Open. 2019;9(11):e031663.","journal-title":"BMJ Open"},{"key":"4693_CR19","unstructured":"Department of Health- South Africa. Annual report 2022\/2023 South Africa: National Department of Health, Republic of South Africa; 2023. www.gov.za\/sites\/default\/files\/gcis_document\/202310\/health-annual-report.pdf."},{"key":"4693_CR20","unstructured":"National Institute for Communicable Disease (NICD). South African Tuberculosis Drug Resistance Survey 2012\u201314: Division of the National Health Laboratory Service; 2017. https:\/\/www.nicd.ac.za\/assets\/files\/K-12750%20NICD%20National%20Survey%20Report_Dev_V11-LR.pdf."},{"issue":"7","key":"4693_CR21","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/S1473-3099(18)30222-6","volume":"18","author":"NA Ismail","year":"2018","unstructured":"Ismail NA, Mvusi L, Nanoo A, Dreyer A, Omar SV, Babatunde S, et al. Prevalence of drug-resistant tuberculosis and imputed burden in South Africa: a national and sub-national cross-sectional survey. Lancet Infect Dis. 2018;18(7):779\u201387.","journal-title":"Lancet Infect Dis"},{"issue":"6","key":"4693_CR22","volume":"6","author":"DJ Horne","year":"2019","unstructured":"Horne DJ, Kohli M, Zifodya JS, Schiller I, Dendukuri N, Tollefson D, et al. Xpert MTB\/RIF and Xpert MTB\/RIF Ultra for pulmonary tuberculosis and rifampicin resistance in adults. Cochrane Database Syst Rev. 2019;6(6):Cd009593.","journal-title":"Cochrane Database Syst Rev"},{"key":"4693_CR23","doi-asserted-by":"crossref","unstructured":"Zifodya JS, Kreniske JS, Schiller I, Kohli M, Dendukuri N, Schumacher SG, et al. Xpert Ultra versus Xpert MTB\/RIF for pulmonary tuberculosis and rifampicin resistance in adults with presumptive pulmonary tuberculosis. Cochrane Database Syst Rev. 2021;2(2):CD009593.","DOI":"10.1002\/14651858.CD009593.pub5"},{"key":"4693_CR24","unstructured":"Department of Health- South Africa. Annual report 2021\/2022 South Africa: National Department of Health, Republic of South Africa; 2022. https:\/\/www.gov.za\/sites\/default\/files\/gcis_document\/202210\/healthannualreport202122.pdf."},{"issue":"1","key":"4693_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-021-95331-w","volume":"11","author":"M Osman","year":"2021","unstructured":"Osman M, van Schalkwyk C, Naidoo P, Seddon JA, Dunbar R, Dlamini SS, et al. Mortality during tuberculosis treatment in South Africa using an 8-year analysis of the national tuberculosis treatment register. Sci Rep. 2021;11(1):1\u201310.","journal-title":"Sci Rep"},{"issue":"1","key":"4693_CR26","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-022-07861-x","volume":"22","author":"H Pai","year":"2022","unstructured":"Pai H, Ndjeka N, Mbuagbaw L, Kaniga K, Birmingham E, Mao G, et al. Bedaquiline safety, efficacy, utilization and emergence of resistance following treatment of multidrug-resistant tuberculosis patients in South Africa: a retrospective cohort analysis. BMC Infect Dis. 2022;22(1):870.","journal-title":"BMC Infect Dis"},{"issue":"1","key":"4693_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12879-021-06745-w","volume":"21","author":"C Kraef","year":"2021","unstructured":"Kraef C, Bentzon A, Panteleev A, Skrahina A, Bolokadze N, Tetradov S, et al. Delayed diagnosis of tuberculosis in persons living with HIV in Eastern Europe: associated factors and effect on mortality\u2014a multicentre prospective cohort study. BMC Infect Dis. 2021;21(1):1\u201312.","journal-title":"BMC Infect Dis"},{"key":"4693_CR28","volume":"2020","author":"Y Xie","year":"2020","unstructured":"Xie Y, Han J, Yu W, Wu J, Li X, Chen H. Survival analysis of risk factors for mortality in a cohort of patients with tuberculosis. Can Respir J. 2020;2020:1654653.","journal-title":"Can Respir J"},{"issue":"3","key":"4693_CR29","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0092077","volume":"9","author":"G Lui","year":"2014","unstructured":"Lui G, Wong RYK, Li F, Lee MKP, Lai RWM, Li TCM, et al. High mortality in adults hospitalized for active tuberculosis in a low HIV prevalence setting. PLoS One. 2014;9(3):e92077.","journal-title":"PLoS One"},{"issue":"3","key":"4693_CR30","first-page":"429","volume":"72","author":"CJ Murray","year":"1994","unstructured":"Murray CJ. Quantifying the burden of disease: the technical basis for disability-adjusted life years. Bull World Health Organ. 1994;72(3):429.","journal-title":"Bull World Health Organ"},{"key":"4693_CR31","volume-title":"WHO methods and data sources for global burden of disease estimates 2000-2019","author":"World Health Organization","year":"2020","unstructured":"World Health Organization. WHO methods and data sources for global burden of disease estimates 2000-2019. WHO; 2020."},{"key":"4693_CR32","volume-title":"Global Health Observatory data repository. Life tables by country_South Africa","author":"World Health Organization","year":"2020","unstructured":"World Health Organization. Global Health Observatory data repository. Life tables by country_South Africa. Geneva: WHO; 2020."},{"issue":"10","key":"4693_CR33","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1056\/NEJMoa1901814","volume":"382","author":"F Conradie","year":"2020","unstructured":"Conradie F, Diacon AH, Ngubane N, Howell P, Everitt D, Crook AM, et al. Treatment of highly drug-resistant pulmonary tuberculosis. N Engl J Med. 2020;382(10):893\u2013902.","journal-title":"N Engl J Med"},{"key":"4693_CR34","volume":"45","author":"SC Mendelsohn","year":"2022","unstructured":"Mendelsohn SC, Fiore-Gartland A, Awany D, Mulenga H, Mbandi SK, Tameris M, et al. Clinical predictors of pulmonary tuberculosis among South African adults with HIV. Eclin Med. 2022;45:101328.","journal-title":"Eclin Med"},{"issue":"6","key":"4693_CR35","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1097\/00005650-199806000-00002","volume":"36","author":"MR Gold","year":"1998","unstructured":"Gold MR, Franks P, McCoy KI, Fryback DG. Toward consistency in cost-utility analyses - using national measures to create condition-specific values. Med Care. 1998;36(6):778\u201392.","journal-title":"Med Care"},{"issue":"1","key":"4693_CR36","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0029775","volume":"7","author":"W Kittikraisak","year":"2012","unstructured":"Kittikraisak W, Kingkaew P, Teerawattananon Y, Yothasamut J, Natesuwan S, Manosuthi W, et al. Health related quality of life among patients with tuberculosis and HIV in Thailand. PLoS One. 2012;7(1):e29775.","journal-title":"PLoS One"},{"key":"4693_CR37","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.659675","volume":"12","author":"H-Y Park","year":"2021","unstructured":"Park H-Y, Cheon H-B, Choi SH, Kwon J-W. Health-related quality of life based on EQ-5D utility score in patients with tuberculosis: a systematic review. Front Pharmacol. 2021;12:659675.","journal-title":"Front Pharmacol"},{"issue":"4","key":"4693_CR38","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1111\/j.1524-4733.2008.00489.x","volume":"12","author":"M Drummond","year":"2009","unstructured":"Drummond M, Barbieri M, Cook J, Glick HA, Lis J, Malik F, et al. Transferability of economic evaluations across jurisdictions: ISPOR good research practices task force report. Value Health. 2009;12(4):409\u201318.","journal-title":"Value Health"},{"issue":"9","key":"4693_CR39","doi-asserted-by":"publisher","first-page":"767","DOI":"10.2165\/11314120-000000000-00000","volume":"27","author":"S Knies","year":"2009","unstructured":"Knies S, Evers SMAA, Candel MJJM, Severens JL, Ament AJHA. Utilities of the EQ-5D. Pharmacoeconomics. 2009;27(9):767\u201379.","journal-title":"Pharmacoeconomics"},{"issue":"1","key":"4693_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2334-13-352","volume":"13","author":"M Shah","year":"2013","unstructured":"Shah M, Chihota V, Coetzee G, Churchyard G, Dorman SE. Comparison of laboratory costs of rapid molecular tests and conventional diagnostics for detection of tuberculosis and drug-resistant tuberculosis in South Africa. BMC Infect Dis. 2013;13(1):1\u20137.","journal-title":"BMC Infect Dis"},{"issue":"2","key":"4693_CR41","doi-asserted-by":"publisher","first-page":"216","DOI":"10.5588\/ijtld.14.0565","volume":"19","author":"TB Diagnostics Market Analysis Consortium","year":"2015","unstructured":"TB Diagnostics Market Analysis Consortium. Market assessment of tuberculosis diagnostics in South Africa, 2012-2013. Int J Tuberc Lung Dis. 2015;19(2):216\u201322.","journal-title":"Int J Tuberc Lung Dis"},{"issue":"1","key":"4693_CR42","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0054587","volume":"8","author":"A Pooran","year":"2013","unstructured":"Pooran A, Pieterson E, Davids M, Theron G, Dheda K. What is the cost of diagnosis and management of drug resistant tuberculosis in South Africa? PLoS One. 2013;8(1):e54587.","journal-title":"PLoS One"},{"issue":"10","key":"4693_CR43","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1111\/tmi.12544","volume":"20","author":"H Cox","year":"2015","unstructured":"Cox H, Ramma L, Wilkinson L, Azevedo V, Sinanovic E. Cost per patient of treatment for rifampicin\u2010resistant tuberculosis in a community\u2010based programme in Khayelitsha, South Africa. Trop Med Int Health. 2015;20(10):1337\u201345.","journal-title":"Trop Med Int Health"},{"key":"4693_CR44","volume-title":"Diagnostics, medical devices & other health products catalog Geneva","author":"Stop TB Partnership","year":"2024","unstructured":"Stop TB Partnership. Diagnostics, medical devices & other health products catalog Geneva. WHO; 2024."},{"key":"4693_CR45","unstructured":"African Society for Laboratory Medicine (ASLM). Molecular Diagnostic Pricing Database: ASLM; 2023. https:\/\/aslm.org\/diagnostic-pricing-database\/."},{"issue":"2","key":"4693_CR46","doi-asserted-by":"publisher","first-page":"172","DOI":"10.5588\/ijtld.14.0421","volume":"19","author":"E Sinanovic","year":"2015","unstructured":"Sinanovic E, Ramma L, Vassall A, Azevedo V, Wilkinson L, Ndjeka N, et al. Impact of reduced hospitalisation on the cost of treatment for drug-resistant tuberculosis in South Africa. Int J Tuberc Lung Dis. 2015;19(2):172\u20138.","journal-title":"Int J Tuberc Lung Dis"},{"issue":"1","key":"4693_CR47","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-018-3013-0","volume":"18","author":"EJ Groessl","year":"2018","unstructured":"Groessl EJ, Ganiats TG, Hillery N, Trollip A, Jackson RL, Catanzaro DG, et al. Cost analysis of rapid diagnostics for drug-resistant tuberculosis. BMC Infect Dis. 2018;18(1):102.","journal-title":"BMC Infect Dis"},{"issue":"2","key":"4693_CR48","doi-asserted-by":"publisher","DOI":"10.1099\/acmi.0.000740.v3","volume":"6","author":"TJ Bagratee","year":"2024","unstructured":"Bagratee TJ, Studholme DJ. Targeted genome sequencing for tuberculosis drug susceptibility testing in South Africa: a proposed diagnostic pipeline. Access Microbiol. 2024;6(2):000740.","journal-title":"Access Microbiol"},{"key":"4693_CR49","unstructured":"Department of Health South Africa. Uniform patient fee schedule: Department of Health; 2022. http:\/\/www.health.gov.za\/uniform-patient-fee-schedule\/."},{"issue":"11","key":"4693_CR50","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001347","volume":"9","author":"NA Menzies","year":"2012","unstructured":"Menzies NA, Cohen T, Lin H-H, Murray M, Salomon JA. Population health impact and cost-effectiveness of tuberculosis diagnosis with Xpert MTB\/RIF: a dynamic simulation and economic evaluation. PLoS Med. 2012;9(11):e1001347.","journal-title":"PLoS Med"},{"issue":"1","key":"4693_CR51","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-020-4795-4","volume":"20","author":"A Mpobela Agnarson","year":"2020","unstructured":"Mpobela Agnarson A, Wang XC, Potluri R, Bhandari H, Dhir A, Kambili C, et al. Long-term impact of the adoption of bedaquiline-containing regimens on the burden of drug-resistant tuberculosis in China. BMC Infect Dis. 2020;20(1):113.","journal-title":"BMC Infect Dis"},{"key":"4693_CR52","unstructured":"South Africa National Health Laboratory Service. NHLS State Price 2018 https:\/\/paediatrics.org.za\/wp-content\/uploads\/2023\/05\/NHLS-State-Price-List-2018.pdf."},{"key":"4693_CR53","unstructured":"Lister Clinic_South Africa. Pathology \/ laboratory test prices for cash clients 2018. https:\/\/listerclinic.com\/affordable-pathology-laboratory-tests\/downloadable-price-list-pathology-lab-tests-2018-08-24-version-9\/."},{"key":"4693_CR54","volume-title":"Medicines Catalog Geneva","author":"Stop TB Partnership Global Drug Facility","year":"2024","unstructured":"Stop TB Partnership Global Drug Facility. Medicines Catalog Geneva. WHO; 2024."},{"issue":"3","key":"4693_CR55","doi-asserted-by":"publisher","first-page":"61","DOI":"10.5588\/pha.12.0003","volume":"2","author":"J Janson","year":"2012","unstructured":"Janson J, Marais F, Mehtar S, Baltussen R. Costs and process of in-patient tuberculosis management at a central academic hospital, Cape Town, South Africa. Public Health Action. 2012;2(3):61\u20135.","journal-title":"Public Health Action"},{"key":"4693_CR56","unstructured":"United Nations. UN Operational Rates of Exchange 2024 [Available from: https:\/\/treasury.un.org."},{"key":"4693_CR57","unstructured":"Statistics South Africa. Statistical Release P0141 Consumer Price Index Pretoria;2024. https:\/\/www.statssa.gov.za\/publications\/P0141\/P0141February2024.pdf."},{"key":"4693_CR58","volume-title":"Methods for the economic evaluation of health care programmes","author":"MF Drummond","year":"2015","unstructured":"Drummond MF, Sculpher MJ, Claxton K, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes. Oxford university press; 2015."},{"key":"4693_CR59","doi-asserted-by":"crossref","unstructured":"Briggs A, Sculpher M, Claxton K. Decision modelling for health economic evaluation: Oxford University Press, Oxford; 2006. https:\/\/global.oup.com\/academic\/product\/decision-modelling-for-health-economic-evaluation-9780198526629?cc=et&lang=en&.","DOI":"10.1093\/oso\/9780198526629.001.0001"},{"key":"4693_CR60","doi-asserted-by":"publisher","DOI":"10.1596\/0-1952-1606-7","volume-title":"The world health report 2002: reducing risks, promoting healthy life","author":"World Health Organization","year":"2002","unstructured":"World Health Organization. The world health report 2002: reducing risks, promoting healthy life. Geneva: WHO; 2002."},{"issue":"7","key":"4693_CR61","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0288605","volume":"18","author":"G Fekadu","year":"2023","unstructured":"Fekadu G, Wang Y, You JH. Standard diagnostics with and without urine-based lipoarabinomannan testing for tuberculosis disease in HIV-infected patients in a high-burden setting\u2013a cost-effectiveness analysis. PLoS One. 2023;18(7):e0288605.","journal-title":"PLoS One"},{"issue":"5","key":"4693_CR62","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1093\/heapol\/czz152","volume":"35","author":"IP Edoka","year":"2020","unstructured":"Edoka IP, Stacey NK. Estimating a cost-effectiveness threshold for health care decision-making in South Africa. Health Policy Plan. 2020;35(5):546\u201355.","journal-title":"Health Policy Plan"},{"issue":"4","key":"4693_CR63","doi-asserted-by":"publisher","first-page":"e153","DOI":"10.1093\/cid\/ciaf112","volume":"81","author":"JAM Stadler","year":"2025","unstructured":"Stadler JAM, Kuhlin J, Molloy SF, Mtwa N, Hayes C, Maartens G, et al. Treatment outcomes with an oral short course regimen for rifampicin-resistant tuberculosis in a high HIV prevalence, programmatic setting in South Africa. Clin Infect Dis. 2025;81(4):e153\u201362.","journal-title":"Clin Infect Dis"},{"issue":"9","key":"4693_CR64","doi-asserted-by":"publisher","first-page":"e3563","DOI":"10.1093\/cid\/ciaa1894","volume":"73","author":"I Tack","year":"2021","unstructured":"Tack I, Dumicho A, Ohler L, Shigayeva A, Bulti AB, White K, et al. Safety and effectiveness of an all-oral, bedaquiline-based, shorter treatment regimen for rifampicin-resistant tuberculosis in high human immunodeficiency virus (HIV) burden rural South Africa: a retrospective cohort analysis. Clin Infect Dis. 2021;73(9):e3563\u201371.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"4693_CR65","first-page":"187","volume":"35","author":"Q Li","year":"2013","unstructured":"Li Q, Xia H, Ou X, Zhao B, Pang Y, Zhao Y. Cost comparison analysis of line probe assay and conventional drug susceptibility testing for diagnosis of drug resistance of Mycobacteria tuberculosis. Chin J Antitubercul. 2013;35(3):187\u201390.","journal-title":"Chin J Antitubercul"},{"key":"4693_CR66","doi-asserted-by":"publisher","DOI":"10.1590\/0037-8682-0755-2020","volume":"54","author":"SCA Silva","year":"2021","unstructured":"Silva SCA, Vater MC, Ramalho DMdP, Almeida INd, Miranda SSd, Kritski A. Cost-effectiveness of Xpert\u00ae MTB\/RIF in the diagnosis of tuberculosis: pragmatic study. Rev Soc Bras Med Trop. 2021;54:e07552020.","journal-title":"Rev Soc Bras Med Trop"},{"key":"4693_CR67","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2023.1204064","volume":"11","author":"L de Araujo","year":"2023","unstructured":"de Araujo L, Cabibbe AM, Mhuulu L, Ruswa N, Dreyer V, Diergaardt A, et al. Implementation of targeted next-generation sequencing for the diagnosis of drug-resistant tuberculosis in low-resource settings: a programmatic model, challenges, and initial outcomes. Front Public Health. 2023;11:1204064.","journal-title":"Front Public Health"}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12916-026-04693-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-026-04693-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-026-04693-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T14:03:35Z","timestamp":1773324215000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12916-026-04693-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,9]]},"references-count":67,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4693"],"URL":"https:\/\/doi.org\/10.1186\/s12916-026-04693-3","relation":{},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,9]]},"assertion":[{"value":"11 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. This study is a decision-analytic cost-effectiveness modeling study based exclusively on published, publicly available, aggregated, and de-identified data obtained from scientific literature and public health reports. It did not involve direct interaction with human participants, nor did it involve access to individual-level patient data or identifiable records. Therefore, institutional ethics approval and informed consent were not required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable\n                      .","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"152"}}